Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Rheumatoid Arthritis

  Free Subscription


Articles published in Curr Opin Rheumatol

Retrieve available abstracts of 27 articles:
HTML format
Text format



Single Articles


    April 2017
  1. BRAGAZZI NL, Watad A, Neumann SG, Simon M, et al
    Vitamin D and rheumatoid arthritis: an ongoing mystery.
    Curr Opin Rheumatol. 2017 Apr 29. doi: 10.1097/BOR.0000000000000397.
    PubMed     Text format     Abstract available


  2. ATZENI F, Masala IF, di Franco M, Sarzi-Puttini P, et al
    Infections in rheumatoid arthritis.
    Curr Opin Rheumatol. 2017 Apr 18. doi: 10.1097/BOR.0000000000000389.
    PubMed     Text format     Abstract available


    March 2017
  3. COHEN S, Kay J
    Biosimilars: implications for rheumatoid arthritis therapy.
    Curr Opin Rheumatol. 2017 Mar 16. doi: 10.1097/BOR.0000000000000379.
    PubMed     Text format     Abstract available


  4. HSIAO B, Fraenkel L
    Incorporating the patient's perspective in outcomes research.
    Curr Opin Rheumatol. 2017;29:144-149.
    PubMed     Text format     Abstract available


  5. VAN DER WOUDE D, Toes RE
    The contribution of autoantibodies to post-translationally modified proteins to inflammatory arthritis.
    Curr Opin Rheumatol. 2017;29:195-200.
    PubMed     Text format     Abstract available


  6. HAHN M, Frey S, Hueber AJ
    The novel interleukin-1 cytokine family members in inflammatory diseases.
    Curr Opin Rheumatol. 2017;29:208-213.
    PubMed     Text format     Abstract available


    February 2017
  7. JOHNSON C
    Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease.
    Curr Opin Rheumatol. 2017 Feb 15. doi: 10.1097/BOR.0000000000000380.
    PubMed     Text format     Abstract available


  8. MYASOEDOVA E
    Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.
    Curr Opin Rheumatol. 2017 Feb 15. doi: 10.1097/BOR.0000000000000378.
    PubMed     Text format     Abstract available


  9. KATZ P
    Causes and consequences of fatigue in rheumatoid arthritis.
    Curr Opin Rheumatol. 2017 Feb 15. doi: 10.1097/BOR.0000000000000376.
    PubMed     Text format     Abstract available


    December 2016
  10. ANSBORO S, Roelofs AJ, De Bari C
    Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both?
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  11. ENGLAND BR, Thiele GM, Mikuls TR
    Anticitrullinated protein antibodies: origin and role in the pathogenesis of rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  12. DOUGADOS M
    Comorbidities in rheumatoid arthritis.
    Curr Opin Rheumatol. 2016;28:282-8.
    PubMed     Text format     Abstract available


  13. MANKIA K, Emery P
    A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals.
    Curr Opin Rheumatol. 2016;28:260-6.
    PubMed     Text format     Abstract available


  14. KADO R, Sanders G, McCune WJ
    Suppression of normal immune responses after treatment with rituximab.
    Curr Opin Rheumatol. 2016;28:251-8.
    PubMed     Text format     Abstract available


    March 2016
  15. LANDEWE R, van der Heijde D
    New concepts of clinical trials in rheumatoid arthritis: a boom of noninferiority trials.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  16. FRIEDMAN MA, Winthrop K
    Vaccinations for rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  17. NAM JL
    Rheumatoid arthritis management of early disease.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  18. VAN DER GOES MC, Jacobs JW, Bijlsma JW
    Rediscovering the therapeutic use of glucocorticoids in rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  19. EMERY P
    Introduction: the future of rheumatoid arthritis management.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format    


  20. DEKKERS J, Toes RE, Huizinga TW, van der Woude D, et al
    The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available



  21. The lung in rheumatoid arthritis, cause or consequence? Erratum.
    Curr Opin Rheumatol. 2016;28:1.
    PubMed     Text format     Abstract available


  22. COSWAY E, Anderson G, Garside P, Prendergast C, et al
    The thymus and rheumatology: should we care?
    Curr Opin Rheumatol. 2016;28:189-95.
    PubMed     Text format     Abstract available


    February 2016
  23. IANCULESCU I, Weisman MH
    Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction: what have we learned over the last year about tumor necrosis factor inhibitors in rheumatoid arthritis?
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  24. MATHEW AJ, Danda D, Conaghan PG
    MRI and ultrasound in rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  25. CHEMIN K, Klareskog L, Malmstrom V
    Is rheumatoid arthritis an autoimmune disease?
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  26. CHATZIDIONISYOU A, Catrina AI
    The lung in rheumatoid arthritis, cause or consequence?
    Curr Opin Rheumatol. 2016;28:76-82.
    PubMed     Text format     Abstract available


    May 2015
  27. TOES RE, Huizinga TJ
    Update on autoantibodies to modified proteins.
    Curr Opin Rheumatol. 2015;27:262-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: